GlassScriptPhysician profile
Sandra Vandemaele
NPI 1366696965
$6,704.37
in general payments reported to CMS, 2019-2025
26 companies · $630 in 2025
The $630 reported for 2025 was more than what 77% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,681 · 2022: $911 · 2023: $1,015 · 2024: $1,467 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,012 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,012.27 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,679.21 | 2021-2025 | Enhertu, Injectafer |
| Amgen INC. | $669.65 | 2021-2025 | Evenity, Prolia, Tezspire |
| Seagen INC. | $612.49 | 2021-2023 | Tukysa |
| Janssen Biotech, INC. | $415.18 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $415.14 | 2021-2025 | Fasenra, Saphnelo |
| Puma Biotechnology, INC. | $377.78 | 2021-2025 | |
| Organon LLC | $350.91 | 2022-2025 | Renflexis, Hadlima |
| Genentech USA, INC. | $328.62 | 2021-2025 | Xolair, Ocrevus Zunovo, Ocrevus |
| Eisai INC. | $282.72 | 2021-2022 | |
| Pfizer INC. | $240.67 | 2021-2024 | |
| Glaxosmithkline, LLC. | $205.43 | 2021-2024 | Nucala, Benlysta |
| Merck Sharp & Dohme LLC | $197.13 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $177.06 | 2023-2025 | Ultomiris |
| Myovant Sciences INC. | $159.48 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.99 | 2021 | |
| Celgene Corporation | $74.59 | 2021-2024 | Reblozyl |
| Genzyme Corporation | $53.05 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.70 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $48.58 | 2021 | |
| Genmab U.S., INC. | $39.50 | 2021-2022 | |
| Gilead Sciences, INC. | $31.37 | 2025 | Trodelvy |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Lilly USA, LLC | $17.21 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.60 | 2021 | |
| Clovis Oncology, INC. | $15.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Vandemaele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.